Background. The optimal management of spinal cord astrocytomas remains to be defined, as aggressive surgery and radiotherapy are associated with a high risk of morbidity. The value of chemotherapy has not been assessed. Procedure. The patient in the present report harbored an infiltrating spinal co
Chemotherapy for spinal cord astrocytoma
β Scribed by Foreman, Nicholas K.; Hay, Thomas C.; Handler, Michael
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 265 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. Factors that could optimize the management of pediatric spinal cord astrocytoma remain unclear and controversial. ## METHODS. To determine the factors that influence the prognosis of pediatric patients with spinal cord astrocytomas, a series of 73 consecutive patients at 13 Fren
Fourteen patients with intramedullary spinal cord astrocytoma (Grades I, 11) or glioblastoma (Grades 111, IV) were seen at a major referral center over a 19-year period. Although similar surgical and radiotherapeutic techniques were used for each group, the nine patients with astrocytoma had a five-
Intrathecal chemotherapy has been deter-ALL after receiving intrathecal methotrexate mined to cause transient or permanent parapare-therapy during the induction and CNS therapy sis due to myelopathy in patients with leukemia phases when compared with their controls. The or other malignancies. To sys
## Background: High grade astrocytomas account for approximately 40% of all primary brain tumors. the median survival is approximately 8-10 months for patients with glioblastoma multiforme and 36 months for patients with anaplastic astrocytoma. the results of systemic chemotherapy in the treatment